CO6420322A2 - Anticuerpos anti-mst1r y usos de los mismos - Google Patents

Anticuerpos anti-mst1r y usos de los mismos

Info

Publication number
CO6420322A2
CO6420322A2 CO11106887A CO11106887A CO6420322A2 CO 6420322 A2 CO6420322 A2 CO 6420322A2 CO 11106887 A CO11106887 A CO 11106887A CO 11106887 A CO11106887 A CO 11106887A CO 6420322 A2 CO6420322 A2 CO 6420322A2
Authority
CO
Colombia
Prior art keywords
antibodies
mst1r
diseases
conditions
antigen binding
Prior art date
Application number
CO11106887A
Other languages
English (en)
Inventor
Reimi Kawaida
Toshiaki Ohtsuka
Ulrike Schubert
Sandra Miller
Philip Rodley
Toshinori Agatsuma
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6420322A2 publication Critical patent/CO6420322A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona regiones de enlace al antígeno recombinante y anticuerpos y fragmentos funcionales que contienen dichas regiones de enlace del antígeno que son específicas para el MST1R, el cual juega un rol integral en diferentes enfermedades o padecimientos tales como el cáncer. Estos anticuerpos, por consiguiente, pueden ser utilizados para tratar estas y otras enfermedades y padecimientos. Los anticuerpos de la descripción también pueden ser utilizados en el campo de los diagnósticos, así como para la investigación adicional del rol del MST1R en el progreso de enfermedades asociadas con tumores. La descripción también proporciona secuencias de ácido nucleico que codifican los anticuerpos anteriores, vectores que contienen los mismos, composiciones farmacéuticas y equipos con instrucciones de uso.
CO11106887A 2009-02-10 2011-08-23 Anticuerpos anti-mst1r y usos de los mismos CO6420322A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15141109P 2009-02-10 2009-02-10

Publications (1)

Publication Number Publication Date
CO6420322A2 true CO6420322A2 (es) 2012-04-16

Family

ID=42227811

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11106887A CO6420322A2 (es) 2009-02-10 2011-08-23 Anticuerpos anti-mst1r y usos de los mismos

Country Status (19)

Country Link
US (1) US9403909B2 (es)
EP (1) EP2396084B1 (es)
JP (1) JP5714511B2 (es)
KR (1) KR101745025B1 (es)
CN (1) CN102438702B (es)
AU (1) AU2010214301B2 (es)
BR (1) BRPI1007979A2 (es)
CA (1) CA2752136C (es)
CO (1) CO6420322A2 (es)
ES (1) ES2583281T3 (es)
HK (1) HK1164193A1 (es)
IL (1) IL214527A0 (es)
MX (1) MX2011008456A (es)
NZ (1) NZ594452A (es)
RU (1) RU2534890C2 (es)
SG (2) SG173196A1 (es)
TW (1) TWI480050B (es)
WO (1) WO2010093055A1 (es)
ZA (1) ZA201105725B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682451C2 (ru) * 2012-04-27 2019-03-19 Дайичи Санкио Компани, Лимитед Антитела к robo4
IL302932A (en) 2015-09-24 2023-07-01 Daiichi Sankyo Co Ltd Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
WO2018038684A1 (en) * 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
DE60041119D1 (de) 1999-07-20 2009-01-29 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
EP1773881A4 (en) * 2004-05-13 2008-08-06 Imclone Systems Inc Inhibition of macrophage-stimulating protein receptor (RON)
RU2007101294A (ru) * 2004-06-15 2008-07-20 Нестек С.А. (Ch) Аэрированные забеливатели и способы
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
CL2008003449A1 (es) * 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
BRPI0906498A2 (pt) * 2008-01-22 2015-07-14 Biogen Idec Inc Anticorpo ron e seus usos

Also Published As

Publication number Publication date
KR101745025B1 (ko) 2017-06-20
CA2752136A1 (en) 2010-08-19
RU2534890C2 (ru) 2014-12-10
MX2011008456A (es) 2011-09-26
CN102438702A (zh) 2012-05-02
CA2752136C (en) 2016-03-15
JP2012517223A (ja) 2012-08-02
IL214527A0 (en) 2011-09-27
TWI480050B (zh) 2015-04-11
US9403909B2 (en) 2016-08-02
BRPI1007979A2 (pt) 2017-10-03
AU2010214301B2 (en) 2016-11-10
ZA201105725B (en) 2012-04-25
SG173196A1 (en) 2011-08-29
NZ594452A (en) 2013-01-25
WO2010093055A1 (en) 2010-08-19
SG2014009195A (en) 2014-04-28
KR20110117677A (ko) 2011-10-27
RU2011137405A (ru) 2013-03-20
US20120034215A1 (en) 2012-02-09
ES2583281T3 (es) 2016-09-20
CN102438702B (zh) 2016-03-02
EP2396084A1 (en) 2011-12-21
TW201036635A (en) 2010-10-16
JP5714511B2 (ja) 2015-05-07
EP2396084B1 (en) 2016-05-11
AU2010214301A1 (en) 2011-09-01
HK1164193A1 (zh) 2012-09-21

Similar Documents

Publication Publication Date Title
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2018000422A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
WO2016187220A3 (en) Anti-ror1 antibodies
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
ECSP10010191A (es) Anticuerpos antimesotelina y usos de los mismos
CR20170138A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
BR112017019914A2 (pt) receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
EA201690868A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
AR115389A1 (es) Anticuerpo antagonista de cd73
EA201692103A1 (ru) Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл)
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
DOP2013000111A (es) Anticuerpos neutralizadores anti-ccl20
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
AR091649A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos

Legal Events

Date Code Title Description
FG Application granted